天津医药

• 实验研究 • 上一篇    下一篇

奥美沙坦酯对慢性心力衰竭小鼠的保护作用

卢晓梅,王巍,于艳秋   

  1. 中国医科大学基础医学院病理生理学教研室
  • 收稿日期:2011-09-02 修回日期:2012-03-02 出版日期:2012-09-15 发布日期:2012-09-15
  • 通讯作者: 卢晓梅

The protect effect of olmesartan medoxomil on chronic heart failure mice

  • Received:2011-09-02 Revised:2012-03-02 Published:2012-09-15 Online:2012-09-15

PDF (PC)

2590

摘要： 目的：奥美沙坦酯对慢性心力衰竭小鼠的保护作用。方法：健康C57小鼠分为假手术组（SHAM组）、慢性心力衰竭组（CHF组）和奥美沙坦酯治疗组（OLM组）。以冠状动脉左前降支结扎法建立慢性心力衰竭小鼠模型，其中奥美沙坦酯治疗组以10mg/kg剂量每日胃饲，4周时观察各组小鼠心率，血压及一般状况，血浆和心脏血管紧张素Ⅱ水平；Real-time PCR法检测心脏AT1R、Ⅰ、Ⅲ型胶原的表达情况，AZAN染色观察心脏组织结构变化。结果：与SHAM组相比，CHF组收缩压显著增高，OLM组较CHF组显著降低（P＜0.05）。与SHAM组相比，CHF组血浆和心脏血管紧张素Ⅱ水平增高， AT1R和Ⅰ、Ⅲ型胶原的表达增高（P＜0.05），OLM组心脏血管紧张素Ⅱ水平，AT1R和Ⅰ、Ⅲ型胶原的表达较CHF组均显著降低（P＜0.05）。CHF组AZAN染色可见心肌组织中梗死区蓝染，心肌纤维消失，代之以纤维结缔组织， OLM组亦可见蓝染的纤维结缔组织，但与CHF组相比面积减少。结论：慢性心力衰竭可使心内肾素血管紧张素系统激活并导致心脏损伤，奥美沙坦酯通过抑制血管紧张素Ⅱ起到心脏保护作用。

关键词: 奥美沙坦酯, 慢性心力衰竭, 心脏损伤

Abstract: AIM : To investigate The protect effect of olmesartan medoxomil on chronic heart failure mice METHODS: C57 mice were divided into sham operation group (SHAM group), chronic heart failure group (CHF group) and olmesartan medoxomil treatment group (OLM group). Experimental CHF models were established by coronary artery ligation, in which OLM group fed with a daily dose of 10mg/kg. The heart rate, blood pressure, plasma and cardiac angiotensin Ⅱ levels; Real-time PCR detection of cardiac AT1R, type Ⅰ, Ⅲ collagen expression,and AZAN staining of cardiac pathological changes were determined after 4 weeks,．RESULTS: Compared with SHAM group, systolic blood pressure, plasma and cardiac angiotensin Ⅱ levels, AT1R and Ⅰ, Ⅲ type collagen expression were increased in CHF group (P <0.05), while in OLM Group ,they were significantly lower than that in CHF group except for the plasma angiotensin Ⅱ levels (P <0.05). AZAN staining of myocardial infarction in the CHF group were blue-stained , the myocardial fibers were disappear and replaced by fibrous connective tissue, OLM Group also can see the blue-stained fibrous connective tissue, but the area is reduced compared with the CHF group. CONCLUSION: Chronic heart failure can activate the intracardiac renin-angiotensin system and leading to heart damage,olmesartan medoxomil can protect heart by inhibiting the effects of angiotensin Ⅱ.

Key words: olmesartan medoxomi, chronic heart failure, heart damage